NIRsupreme Ridaforolimus-Eluting Coronary Stent System: Phase II started

Medinol began the single-blind, international Phase II BIONICS trial to compare NIRsupreme Ridaforolimus-Eluting Coronary Stent System vs. Endeavor Resolute Zotarolimus-Eluting Stent in about 1,900 patients. The start of the trial - along with the start of the Phase II NIREUS trial and the submission of an IDE to FDA - triggered milestone payments of $3.8 million to Ariad. The Phase II NIREUS trial is comparing the NIRsupreme stent vs. Endeavor Resolute zotarolimus-eluting stent in about 300 patients. ...